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BACKGROUND AND
SIGNIFICANCE
 Patent ductus arteriosus is a congenital
disorder in neonates in which the vessel
fails to close after birth and remains patent
or open (Jinmiao, Jing, Qin, & Zhiping,
2017).
 Delayed closure of ductus arteriosus (PDA)
in preterm infants under 28 weeks is
associated with high incidence of pulmonary
hemorrhage, intraventricular hemorrhage
(IVH), necrotizing enterocolitis (NEC),
chronic lung disease and high mortality
(Bhat & Das, 2015).
 Therefore, closure of the PDA is essential to
prevent these complications and to improve
both cardiorespiratory status and survival
rate (El-Mashad, El-Mahdy, El Amrousy,
Elgendy, & El-Mashad, 2017).
 Initially indomethacin was the drug of choice
for treating PDA; however it can affect renal,
gastrointestinal and cerebral organs. These
complications can lead to transient or
permanent renal dysfunctions, necrotizing
enterocolitis, gastrointestinal hemorrhage
and reduced cerebral intracellular
oxygenation (Yang et al., 2013).
 Ibuprofen was introduced and approved by
the FDA as an alternative agent in April
2006 for closure of PDA in premature infants
(Yang, Song & Choi 2013).
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RESEARCH QUESTION
“Does Ibuprofen compared to Indomethacin
have the same efficacy with fewer adverse
effects in treating patent ductus arteriosus in a
preterm infant”?
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METHODOLOGY

 An integrated review of the literature was
conducted using the methodology described
by Whittemore and Knafl (2005) and Brown
(2018).
 Cochrane, CINAHL, Medline Complete and
Pub Med were searched using the following
key terms “ibuprofen”, and “indomethacin”,
and “patent ductus arteriosus”.
 Search criteria was limited to “full text
articles” between the years 2013-2018 for all
databases.
 Inclusion criteria included studies involving
the evaluation of the efficacy in closure of
PDA using ibuprofen or indomethacin,
adverse effects related to this treatment
utilizing these medications, routes of
administrations and dosages.
 The original search identified 70 articles.
After screening the articles, 23 duplicate
articles were removed, 1 article was not
available in English, 1 article was not
available in full text and 33 articles were
excluded due to pertaining to surgical
treatment or studying paractemol medication
or not related to this research topic.
 Findings from the studies were synthesized
for comparative analysis of results.

RESULTS
 Seventy articles were initially identified;
twelve included in final sample.
 Level of evidence rated using evidence
pyramid published by Long & Gannaway
and Appraisal Guides by Brown (2015;
2018).

LITERATURE SYNTHESIS
 Ibuprofen was found to as effective as
indomethacin for successful treatment of PDA
closure. This was noted by Ohlsson et al., ElMashad et al., ElHassan et al., Chan et al.,
Pacifici et al., Gulack et al., Loomba et al.,
Yang et al., (2015, 2017, 2014, 2014, 2014,
2015, 2015, 2013).
 Ibuprofen had fewer side effects than
indomethacin but showed to have significant
increase in serum bilirubin levels (ElHassan et
al., 2014).
 Ohlsson et al., Malikiwi et al., ElHassan et al.,
Pacifici et al., Loomba et al., Yang et al., all
found ibuprofen groups had lower creatinine
levels and reduced risk of oliguria compared to
those treated with indomethacin (2015, 2015,
2014 ,2014, 2015, 2013).
 Ibuprofen groups did however have more
pulmonary hypertension compared to those in
the indomethacin group. This was noted by
Malikiwi et al., ElHassan et al., (2015, 2014).
 Jinmiao et al., Mitra et al., found high dose
oral ibuprofen was more effective in closure of
PDA compared to IV ibuprofen and IV
indomethacin, but more studies are needed to
determine long term adverse effects (2017,
2018).

CLINICAL IMPLICATIONS

 Ibuprofen is shown to be as effective as
indomethacin in treatment of PDA closure.
 Ibuprofen does show to have fewer adverse
effects although both medications do come
with significant adverse effects.

CONCLUSION

 Results of this literature have shown
ibuprofen is as effective as indomethacin in
PDA closure.
 However the adverse effects have not been
proven to be majorly different. Further level 1
evidence research is needed to determine
the safest medication for treatment in PDA
closure.
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